Literature DB >> 21170498

[The expression of a novel estrogen receptor, GPR30, in epithelial ovarian carcinoma and its correlation with MMP-9].

Hui-Di Liu1, Yan Yan, Xue-Feng Cao, Pei-Zhu Tan, Hai-Xia Wen, Chun-Mei Lv, Xiao-Mei Li, Guo-Yi Liu.   

Abstract

The aim of the present study is to investigate the expression of a novel estrogen receptor, G protein-coupled receptor 30 (GPR30) and its correlation with matrix metalloproteinases-9 (MMP-9) in epithelial ovarian cancer (EOC). Ovary tissues were obtained from 39 female patients, including 30 cases of EOC and 9 cases of benign ovarian tumor. Four normal ovary tissues were used as control. Immunohistochemical staining was used to detect the expressions of GPR30 and MMP-9. Chi square test, Fisher's exact test and Spearman's rank correlation analysis were used for statistical analysis. The results showed that GPR30 overexpression rate in EOC cases was significantly higher than those in benign ovarian tumor and normal ovary cases. Whereas MMP-9 overexpression rate in EOC cases was significantly higher than that in normal ovary cases, without any difference to that in benign ovarian tumor cases. To demonstrate the relationship between GPR30 and clinicopathological variables of EOC, we further analyzed the pathology type, FIGO stage and age of patients sampled in our study. The analysis showed there were significant differences of GPR30 overexpression rate among various pathology types and different FIGO stages (P<0.05), and no significant difference of both GPR30 and MMP-9 among three age groups (P>0.05). Moreover, GPR30 expression was positively correlated with MMP-9 (r(s)=1.000, P=0.002). These results suggest that GPR30 may be involved in the invasion and metastasis of EOC, being a potential index of EOC early diagnosis and malignancy grade prediction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21170498

Source DB:  PubMed          Journal:  Sheng Li Xue Bao        ISSN: 0371-0874


  4 in total

1.  Baicalein, unlike 4-hydroxytamoxifen but similar to G15, suppresses 17β-estradiol-induced cell invasion, and matrix metalloproteinase-9 expression and activation in MCF-7 human breast cancer cells.

Authors:  Yan Chen; Duan-Yang Hong; Jing Wang; Jun Ling-Hu; Yan-Yan Zhang; Di Pan; Yi-Ni Xu; Ling Tao; Hong Luo; Xiang-Chun Shen
Journal:  Oncol Lett       Date:  2017-06-02       Impact factor: 2.967

Review 2.  The G-protein-coupled estrogen receptor GPER in health and disease.

Authors:  Eric R Prossnitz; Matthias Barton
Journal:  Nat Rev Endocrinol       Date:  2011-08-16       Impact factor: 43.330

3.  The novel estrogen receptor GPER regulates the migration and invasion of ovarian cancer cells.

Authors:  Yan Yan; Huidi Liu; Haixia Wen; Xueli Jiang; Xuefeng Cao; Guangmei Zhang; Guoyi Liu
Journal:  Mol Cell Biochem       Date:  2013-04-12       Impact factor: 3.396

4.  Decreased Expression of GPER1 Gene and Protein in Goiter.

Authors:  Raquel Weber; Ana Paula Santin Bertoni; Laura Walter Bessestil; Ilma Simoni Brum; Tania Weber Furlanetto
Journal:  Int J Endocrinol       Date:  2015-03-12       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.